![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Preclinical Assessments of a Cabotegravir Prodrug
Predicting Human Dosing Durations of >6 Months
|
|
|
AIDS 2024 Munich July 20-26
Mark Baker,1 William Proctor,2 Nick Falco,3 Liangfu Chen,3 Vicki Ironmonger,4 Sebastian Pearce,4 Andrew Weber,5
Max Lataillade6
1ViiV Healthcare, Munchenbuchsee, Switzerland; 2GSK, Waltham, MA, USA; 3GSK, Upper Providence, PA, USA; 4GSK, Stevenage, UK; 5ViiV Healthcare, Durham, NC, USA; 6ViiV Healthcare, Branford, CT, USA
![0730241](../images/073024/073024-11/0730241.gif)
![0730242](../images/073024/073024-11/0730242.gif)
![0730243](../images/073024/073024-11/0730243.gif)
![0730244](../images/073024/073024-11/0730244.gif)
![0730245](../images/073024/073024-11/0730245.gif)
![0730246](../images/073024/073024-11/0730246.gif)
![0730247](../images/073024/073024-11/0730247.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|